Insight Molecular Diagnostics Inc. (LON:0KCC)
5.57
-0.15 (-2.58%)
Feb 12, 2026, 3:42 PM GMT
LON:0KCC Revenue
Insight Molecular Diagnostics had revenue of $260.00K USD in the quarter ending September 30, 2025, with 126.09% growth. This brings the company's revenue in the last twelve months to $4.40M, up 520.87% year-over-year. In the year 2024, Insight Molecular Diagnostics had annual revenue of $1.88M with 25.15% growth.
Revenue (ttm)
$4.40M
Revenue Growth
+520.87%
P/S Ratio
41.23
Revenue / Employee
$89.84K
Employees
49
Market Cap
135.01M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Optima Health | 113.75M |
| Animalcare Group | 81.07M |
| EKF Diagnostics Holdings | 50.22M |
| Tristel | 46.46M |
Insight Molecular Diagnostics News
- 6 months ago - OncoCyte Q2 2025 Earnings Preview - Seeking Alpha
- 8 months ago - Oncocyte changes name to Insight Molecular Diagnostics and moves headquarters to Nashville - Seeking Alpha
- 8 months ago - Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville - GlobeNewsWire
- 9 months ago - Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - GlobeNewsWire
- 9 months ago - OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative - Seeking Alpha
- 9 months ago - OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 months ago - OncoCyte GAAP EPS of -$0.26 misses by $0.02, revenue of $2.13M beats by $2M - Seeking Alpha
- 9 months ago - Oncocyte Reports Q1 2025 Results and Business Progress - GlobeNewsWire